Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Avadel Pharmaceuticals Q4 EPS $(0.32) Misses $(0.29) Estimate, Sales $19.45M Beat $18.11M Estimate

Author: Benzinga Newsdesk | March 04, 2024 07:33am
Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 27.27 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $19.45 million which beat the analyst consensus estimate of $18.11 million by 7.42 percent.

Posted In: AVDL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist